Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADMIRE-CD II: Cx601 versus placebo for complex perianal fistulas in Crohn's disease
MOH_2018-05-09_001964Phase 3Not yet recruiting
- Sponsor
- TiGenix
- Start
- Sep 2017
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease and anal fistula comparing Placebo with Cx601 (2 arms). Primary endpoint: Primary endpoint not provided in registry entry. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
darvadstrocel
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on MOH_2018-05-09_001964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-09_001964.